TRVI logo

TRVITrevi Therapeutics Inc

$13.47
$0.01
(0.07%)
Pre-Market
Updated: 07:38 AM EDT·Prev Close $13.46
EarningsAug 6
Mkt Cap$1.91B
Vol151.00
45

Neutral Sentiment

How do you feel about TRVI?

About

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
34

Frequently Asked Questions

What is Market Cap of Trevi Therapeutics Inc?
What is the 52-week high for Trevi Therapeutics Inc?
What is the 52-week low for Trevi Therapeutics Inc?
What is Trevi Therapeutics Inc stock price today?
What was Trevi Therapeutics Inc stock price yesterday?
What is the PE ratio of Trevi Therapeutics Inc?
What is the Price-to-Book ratio of Trevi Therapeutics Inc?
What is the 50-day moving average of Trevi Therapeutics Inc?
How many employees does Trevi Therapeutics Inc have?

Advertisement|Remove ads.